Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -59.36% is 83% below its 5-year average of -32.43%, near the low end of its 5-year range (-76.07%–-8.77%).
4.63% below its 12-month average of -56.73%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -19.57%.
RETURN ON ASSETS (ROA)
-59.36%
RETURN ON ASSETS (ROA) AVG TTM
-56.73%
RETURN ON ASSETS (ROA) AVG 3Y
-42.41%
RETURN ON ASSETS (ROA) AVG 5Y
-32.43%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-4.63%
CURRENT VS 3Y AVG
-39.96%
CURRENT VS 5Y AVG
-83.03%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.80%
median of 816 covered companies
CURRENT VS SECTOR MEDIAN
-86.67%
vs the sector median at left
Nyxoah S.A.
Market Cap
$144.10M
Return on Assets (ROA)
-59.36%
TTM Avg
-56.73%
3Y Avg
-42.41%
5Y Avg
-32.43%
Market Cap
$142.60M
Return on Assets (ROA)
-39.76%
TTM Avg
-26.00%
3Y Avg
-40.35%
5Y Avg
-34.25%
Market Cap
$144.19M
Return on Assets (ROA)
-96.78%
TTM Avg
-33.63%
3Y Avg
-87.61%
5Y Avg
-84.15%
Market Cap
$141.35M
Return on Assets (ROA)
-92.89%
TTM Avg
-84.34%
3Y Avg
-55.16%
5Y Avg
-43.29%
Market Cap
$145.54M
Return on Assets (ROA)
-90.55%
TTM Avg
-70.80%
3Y Avg
-45.07%
5Y Avg
-40.08%
Market Cap
$139.95M
Return on Assets (ROA)
-28.35%
TTM Avg
-69.97%
3Y Avg
-58.34%
5Y Avg
-49.63%
Market Cap
$145.55M
Return on Assets (ROA)
-20.01%
TTM Avg
-38.20%
3Y Avg
-34.64%
5Y Avg
-39.69%
Market Cap
$139.73M
Return on Assets (ROA)
35.31%
TTM Avg
-14.11%
3Y Avg
-23.46%
5Y Avg
-20.68%
Market Cap
$138.31M
Return on Assets (ROA)
-36.33%
TTM Avg
-27.39%
3Y Avg
-256.74%
5Y Avg
-207.88%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nyxoah S.A. (NYXH) | $144.10M | -59.36% | -56.73% | -42.41% | -32.43% |
| Protara Therapeutics, Inc. (TARA)vs › | $142.60M | -39.76% | -26.00% | -40.35% | -34.25% |
| Korsana Biosciences, Inc. (KRSA)vs › | $144.19M | -96.78% | -33.63% | -87.61% | -84.15% |
| Sutro Biopharma, Inc. (STRO)vs › | $141.35M | -92.89% | -84.34% | -55.16% | -43.29% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $145.54M | -90.55% | -70.80% | -45.07% | -40.08% |
| Immuneering Corporation (IMRX)vs › | $139.95M | -28.35% | -69.97% | -58.34% | -49.63% |
| Anavex Life Sciences Corp. (AVXL)vs › | $145.55M | -20.01% | -38.20% | -34.64% | -39.69% |
| Fortress Biotech, Inc. (FBIOP)vs › | $139.73M | 35.31% | -14.11% | -23.46% | -20.68% |
| Alpha Cognition Inc (ACOG)vs › | $138.31M | -36.33% | -27.39% | -256.74% | -207.88% |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $147.54M | -76.12% | -156.63% | -142.29% | -134.64% |
ROA
-59.4%
ROE
-120.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -76.07% |
| 2024-12-31 | -37.40% |
| 2023-12-31 | -34.80% |
| 2022-12-31 | -21.38% |
| 2021-12-31 | -16.17% |
| 2020-12-31 | -8.77% |
| 2019-12-31 | -49.57% |
| 2018-12-31 | -50.50% |
| 2017-12-31 | -93.06% |
